Monitoring asthma in pregnancy: a discussion paper by Guy Marks
Monitoring asthma in pregnancy 
A discussion paper
 
 
 
 
 
 
Australian Institute of Health and Welfare 
Canberra 
Cat. no. ACM 28 
 
Monitoring asthma in pregnancy 
A discussion paper 
 
    
The Australian Institute of Health and Welfare is a major national agency 
which provides reliable, regular and relevant information and statistics 
on Australia’s health and welfare. The Institute’s mission is 
 authoritative information and statistics to promote better health and wellbeing. 
© Australian Institute of Health and Welfare 2013 
This product, excluding the AIHW logo, Commonwealth Coat of Arms and any material owned by a 
third party or protected by a trademark, has been released under a Creative Commons BY 3.0 
(CC-BY 3.0) licence. Excluded material owned by third parties may include, for example, design and 
layout, images obtained under licence from third parties and signatures. We have made all reasonable 
efforts to identify and label material owned by third parties. 
You may distribute, remix and build upon this work. However, you must attribute the AIHW as the 
copyright holder of the work in compliance with our attribution policy available at 
<www.aihw.gov.au/copyright/>. The full terms and conditions of this licence are available at 
<http://creativecommons.org/licenses/by/3.0/au/>. 
Enquiries relating to copyright should be addressed to the Head of the Media and Strategic 
Engagement Unit, Australian Institute of Health and Welfare, GPO Box 570, Canberra ACT 2601. 
 
ISBN 978-1-74249-491-3 
Suggested citation 
Australian Institute of Health and Welfare: Australian Centre for Asthma Monitoring 2013 (Marks G, 
Reddel H, Guevara-Rattray E & Ampon R). Monitoring asthma in pregnancy: a discussion paper. Cat. 
no. ACM 28. Canberra: AIHW. 
Australian Institute of Health and Welfare 
Board Chair 
Dr Andrew Refshauge 
Director 
David Kalisch 
Any enquiries about or comments on this publication should be directed to: 
Media and Strategic Engagement Unit 
Australian Institute of Health and Welfare 
GPO Box 570 
Canberra ACT 2601 
Tel: (02) 6244 1032 
Email: info@aihw.gov.au 
Published by the Australian Institute of Health and Welfare 
Please check the online version at <www.aihw.gov.au> for any amendments.
   iii 
Contents 
Acknowledgments .............................................................................................................................................. iv 
Abbreviations ....................................................................................................................................................... v 
Summary .............................................................................................................................................................. vi 
1 Introduction ................................................................................................................................................... 1 
2 What does good care for asthma in pregnancy look like? .................................................................... 3 
Effects of pregnancy on asthma outcomes ................................................................................................. 3 
Effects of asthma on pregnancy outcomes ................................................................................................. 5 
Evidence about adverse effects of therapy for asthma during pregnancy ............................................ 6 
Management of asthma during pregnancy ............................................................................................... 6 
3 Developing a monitoring approach for asthma in pregnancy ........................................................... 10 
Existing indicators that are relevant to asthma in pregnancy ............................................................... 10 
Proposed additional indicators specific to pregnancy ........................................................................... 10 
4 Data sources that could be used within a monitoring approach ....................................................... 13 
Existing data sources .................................................................................................................................. 13 
Emerging possibilities for data collection ................................................................................................ 15 
Specific local studies ................................................................................................................................... 16 
5 Discussion ................................................................................................................................................... 18 
Options for data development .................................................................................................................. 18 
Relevance to other common, chronic and complex conditions managed during pregnancy ........... 19 
Glossary ............................................................................................................................................................... 21 
References............................................................................................................................................................ 24 
List of tables ........................................................................................................................................................ 28 
List of boxes ........................................................................................................................................................ 29 
 
 iv  
Acknowledgments 
The authors of this report are Guy Marks, Helen Reddel, Elyse Guevara-Rattray and Rosario 
Ampon of the Australian Centre for Asthma Monitoring (ACAM). 
The report was reviewed by Lisa McGlynn, Louise York and Tomoko Sugiura of the AIHW. 
The ACAM would like to acknowledge the assistance and expertise of Vanessa Murphy and 
the National Perinatal Epidemiology and Statistics Unit during the development of this 
report. The authors also would like to acknowledge the valuable input from the members of 
the National Monitoring of Asthma and Linked Chronic Respiratory Conditions Advisory 
Group. 
This publication was funded by the Australian Government Department of Health and 
Ageing through the Asthma Management Program. 
 
 
 
 
 
  
 
 
 
   v 
Abbreviations 
ABS Australian Bureau of Statistics 
ACAM Australian Centre for Asthma Monitoring 
AIHW Australian Institute of Health and Welfare 
BEACH Bettering the Evaluation and Care of Health 
DoHA Department of Health and Ageing 
GINA Global Initiative for Asthma 
GP general practitioner 
ICD-10-AM International Statistical Classification of Diseases and Related Health 
Problems, Tenth revision, Australian Modification 
ICS inhaled corticosteroid 
LABA long-acting beta-agonists 
NAC National Asthma Council 
NAEPP National Asthma Education and Prevention Program  
NHMRC National Health and Medical Research Council 
MIM Maternity Information Matrix 
NHMD National Hospital Morbidity Database 
NMDS National Minimum Data Set 
NPDC National Perinatal Data Collection 
PCEHR personally controlled electronic health record 
SABA short-acting beta-agonists 
SHS Shared Health Summary 
  
Symbols 
n.a. not available 
 vi  
Summary 
Pregnant women with poorly controlled asthma are at increased risk of experiencing 
pregnancy-induced hypertension and pre-eclampsia. They are also at increased risk of 
having infants that are premature or small for their gestational age.  
Clinical guidelines emphasise the importance of pregnant women with asthma using their 
asthma medications as prescribed. Taking prescribed preventer medicines for asthma is safer 
for pregnant women and their infants than having uncontrolled asthma.  
Asthma can be controlled, and exacerbations of asthma can be prevented, with good care 
during pregnancy. If asthma control is maintained during pregnancy, the outcomes for the 
woman and infant are no different than for women who do not have asthma.  
Currently, in Australia, there is no nationally consistent collection of asthma-management 
data in pregnant women. Improved information about management practices among 
pregnant women with asthma would enable us to: 
• ascertain who is getting good care for asthma during pregnancy  
• identify opportunities for improving care for pregnant women with asthma.  
This report recommends the following indicators of good care for asthma during pregnancy:  
• proportion of pregnant women who have their asthma status documented 
• proportion of pregnant women with asthma who had a review of their asthma during 
the first trimester 
• proportion of pregnant women with asthma who have a 4- to 6-weekly review of their 
asthma during pregnancy. 
Improving data on the management of asthma during pregnancy could be achieved by: 
• augmenting existing national perinatal data 
• enhancing general practice data 
• conducting periodic surveys in the antenatal setting. 
The problems and solutions that have been identified for asthma may have analogous 
application in relation to other common chronic diseases that require management during 
pregnancy, such as diabetes and epilepsy. 
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1 Introduction 
Asthma is a chronic inflammatory condition of the airways associated with episodes of 
wheezing, breathlessness and chest tightness. Asthma is an important condition in pregnant 
women because: 
• asthma is common 
• asthma may have adverse effects on the course of pregnancy and on fetal and infant 
outcomes 
• pregnancy may have adverse effects on asthma control and exacerbations, and asthma 
changes unpredictably in pregnancy  
• some pregnant women and health professionals have concerns about potential adverse 
effects of medicines used to treat asthma during pregnancy.  
Asthma is one of the most common chronic disorders that affect pregnant women. In 
Australia, it was estimated that 11.4% of women aged 15–49 had current asthma in 2011–12 
(ABS 2013). Studies of pregnant women in Western Australia, Newcastle and Melbourne 
have shown that about 12% have current asthma (Clifton et al. 2009; Kurinczuk et al. 1999; 
Sawicki et al. 2011).    
The presence of asthma in pregnant women is associated with an increased risk of adverse 
maternal outcomes, including worsening asthma and pre-eclampsia (see Box 2.1 for 
pregnancy-related terms), and an increased risk of adverse fetal and infant outcomes, 
particularly if the mother experiences an exacerbation of asthma while she is pregnant 
(Murphy et al. 2011). Clinical practice guidelines, based on evidence (Murphy et al. 2006) 
recommend careful management of asthma during pregnancy to reduce these risks (NAC 
2006).     
Little information is available at present on the management of asthma in pregnancy in 
Australia. Population-level monitoring of pregnant women with asthma would support 
assessment of the extent to which management of asthma in pregnancy in Australia is 
consistent with clinical practice guidelines. It would also allow evaluation of the impact of 
asthma on maternal and fetal outcomes.  
The purpose of this report is to: 
• describe a rationale for monitoring asthma in pregnancy 
• develop a proposed approach to monitoring asthma in pregnancy 
• describe the data sources proposed for use within a monitoring approach 
• outline options for further data development required to inform such monitoring. 
Chapter 2 describes what good care for asthma in pregnancy looks like. The chapter first 
examines how pregnancy may have an impact on asthma control and how asthma may affect 
pregnancy and fetal outcomes. This is followed by a review of evidence about possible 
adverse effects of asthma therapy during pregnancy and finally by a summary of clinical 
practice guidelines relevant to the management of asthma in pregnancy, to provide context 
for the identification of appropriate indicators and measures.  
Chapter 3 describes the elements of an approach designed to assess who is getting good care 
for asthma during pregnancy. This chapter also describes how this approach could be used 
to identify opportunities for improving care for pregnant women with asthma. 
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Chapter 4 describes existing data sources that could, potentially, be used within a 
monitoring approach for pregnant women with asthma, and evaluates their suitability for 
this purpose.  
Chapter 5 outlines options for further data development to inform the monitoring approach. 
This chapter also discusses the relevance of these findings to monitoring care for other 
chronic diseases that affect maternal and child outcomes of pregnancy.   
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2 What does good care for asthma in 
pregnancy look like? 
Effects of pregnancy on asthma outcomes 
Although there is currently no established cure for asthma, good management of the 
condition can control the disease and prevent symptoms from occurring or worsening. The 
assessment of asthma control includes assessment of the patient’s current status (for 
example, symptoms, medication use and lung function), as well as their risk of experiencing 
future adverse outcomes such as reduced lung function and episodes of worsening 
symptoms (exacerbations). 
Many women with a history of asthma experience a change in asthma control during 
pregnancy, independent of any change in medication use. It has been estimated that one-
third of pregnant women with asthma experience an improvement in their symptoms, one-
third experience an overall worsening of their symptoms and the remaining one-third are 
overall unchanged (Gluck 2004). This change is most evident between 25 and 32 weeks of 
gestation (Murphy et al. 2005b; Schatz et al. 1988).  
Even among women whose asthma control is unchanged or improved during pregnancy, 
exacerbations of asthma are common. Over half of pregnant women with asthma experience 
an exacerbation of their condition and one-third experience a severe exacerbation (Murphy et 
al. 2005b). Hence, both overall deterioration in asthma control and exacerbations are 
common among pregnant women. 
Women who have severe asthma before they are pregnant are most likely to suffer an 
exacerbation of their asthma during pregnancy (Murphy et al. 2005b; Schatz et al. 2006). 
Other factors increasing the likelihood of exacerbations during pregnancy are mainly related 
to inadequate asthma management before the pregnancy, such as: 
• lack of self-management skills  
• absence of an asthma action plan  
• poor adherence to prescribed inhaled corticosteroids (ICS) use 
• obesity (Hendler et al. 2006). 
These factors increase the risk of deterioration in asthma control during pregnancy 
(Chambers 2003).  
Mechanical, neuro-hormonal and behavioural changes that occur in pregnancy may all 
contribute to the observed changes in asthma control. Some of these changes may cause a 
sensation of breathing difficulty in pregnant women, with or without asthma. Mechanical 
changes to the shape of the chest wall and position of the diaphragm alter the efficiency of 
breathing during pregnancy, particularly in the third trimester (Gluck & Gluck 1976, 2006).  
Stimulation of the respiratory centre in the brain by the hormone progesterone, particularly 
during the first or second trimester, causes a sensation of breathing difficulty (that is, 
shortness of breath) in many women. In pregnant women with asthma, this may be 
perceived as deterioration in asthma control (Gluck & Gluck 2006; Murphy et al. 2011). 
However, progesterone may have more specific effects on airway muscle tone and on airway 
inflammation in women with asthma (Tan & Thomson 2000). The direct mechanism of these 
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changes and the explanation for improvement in some women and deterioration in others 
has not been fully explained.  
Deterioration of asthma symptoms may also arise as an indirect consequence of behavioural 
change during pregnancy. Concerns about the effects of prescribed medication on the fetus 
cause many women to reduce or discontinue their asthma medication during pregnancy, 
either on their own initiative or on medical advice (Beckmann 2002; Chambers 2003; Lim et 
al. 2011a, 2012).  
In a study of women of child-bearing age in the United States, 82% of respondents who used 
ICS were concerned about the perceived risks to their unborn child if they became pregnant 
and, of this group, 36% said that they would discontinue their ICS if they became pregnant 
(Chambers 2003). Similar findings have been found in Australia where almost one-third of 
pregnant women self-reported non-adherence to prescribed ICS before a severe exacerbation 
of asthma (Murphy et al. 2005a).  
Non-adherence to asthma medication may lead to a loss of asthma control and increased risk 
of exacerbations (Murphy et al. 2005a; Schatz & Leibman 2005). Hence, non-adherence to 
asthma medications due to the perceived risk of harm to the developing fetus may lead to 
loss of control of asthma. Evidence about the risk to the fetus associated with medications 
used in the treatment of asthma is presented in Chapter 2 Evidence about adverse effects of 
therapy for asthma during pregnancy.   
Viral respiratory tract infections are also a common cause of exacerbations of asthma during 
pregnancy (Murphy et al. 2006; Schatz & Leibman 2005). Pregnant women appear to be 
particularly susceptible to viral respiratory infections (Cox et al. 2006; Murphy et al. 2005a).  
Pregnant women comprised 7% of people requiring hospital care in the United States during 
the 2009 H1N1 influenza pandemic. Among pregnant women who were hospitalised at that 
time, 22% also had asthma (Jain et al. 2009). Similar observations were made in Australia and 
New Zealand, where 31% of pregnant women admitted to hospital with H1N1 influenza had 
asthma (that is, three times the population prevalence of asthma in women of child-bearing 
age) (Knight et al. 2011).  
Box 2.1: Definitions of pregnancy terms used 
x Pregnancy-induced hypertension: characterised by the onset of hypertension after 
20 weeks gestation without any maternal or fetal features of pre-eclampsia followed by 
return of normal blood pressure 3 months after birth.  
x Pre-eclampsia: a multi–system disorder unique to human pregnancy, which is 
characterised by hypertension and involvement of one or more other organ systems 
and/or the fetus. 
x Small for gestational age: describing a fetus or baby that has failed to reach the 
birthweight expected for its gestational age; that is, below the 10th percentile.  
x Pre-term delivery: birth before 37 weeks of gestation 
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Effects of asthma on pregnancy outcomes 
Outcomes for the mother 
Overall, there is an increased risk of pregnancy-induced hypertension and pre-eclampsia 
among pregnant women who have asthma (Liu et al. 2001; Stenius-Aarniala et al. 1996). 
However, there is some variation among studies. Some studies have shown that women with 
well-controlled asthma are not at increased risk of pre-eclampsia compared with women 
without asthma (Mihrshahi et al. 2007; Murphy et al. 2005c; Stenius-Aarniala et al. 1996).  
Although there is no evidence that exacerbations of asthma during pregnancy are associated 
with an increased risk of pre-eclampsia, the severity of asthma before pregnancy is 
correlated with the risk of gestational hypertension and pre-eclampsia (Murphy & Gibson 
2011). This provides an additional rationale for monitoring asthma and asthma management 
during pregnancy.  
Outcomes for the fetus and infant 
Maternal asthma is associated with an increased risk of low birthweight, small for 
gestational age and pre-term delivery (Enriquez et al. 2007; Murphy et al. 2011). All three 
outcomes are considered adverse for the infant.  
A recent meta-analysis has shown that the birthweight of infants born to mothers with 
asthma is, on average, 93 grams lower than the birthweight of those born to women without 
asthma (Murphy et al. 2011). Furthermore, the risk of having a low birthweight infant was 
2.5 fold higher in mothers who experienced a severe exacerbation of asthma during 
pregnancy than in mothers without asthma (Murphy et al. 2006), and 3 fold higher in 
mothers with an exacerbation of asthma compared with those with no exacerbations during 
pregnancy (Namazy et al. 2013). The magnitude of the effect of severe exacerbations of 
asthma on birthweight is similar to that of maternal smoking during pregnancy (Murphy & 
Gibson 2011). 
Women with asthma have a 1.2 fold increased risk of having a baby who is small for 
gestational age compared with women without asthma (Murphy et al. 2011). Another, more 
recent meta-analysis comparing women with mild to those with moderate/severe asthma 
demonstrated a 1.2 fold increased risk of having a small-for-gestational-age infant for 
women with moderate/severe asthma (Namazy et al. 2013). Among women with asthma 
during pregnancy, regular use of ICS protects against the risk of having a small-for-
gestational-age infant (Jana et al. 1995; Murphy & Gibson 2011).  
Maternal asthma is associated with a 1.4 fold increased risk of pre-term delivery (Murphy et 
al. 2011). This effect was evident only in women who had no active asthma management 
during the pregnancy and was not evident in the women whose asthma was actively 
managed during pregnancy (Murphy et al. 2011). 
Furthermore, maternal asthma is associated with a small, but significantly increased, risk of 
congenital malformations (rate ratio 1.11; 95% confidence interval 1.02–1.21), a 45% increased 
risk of death within the first 28 days of life and a 50% increased risk of neonatal 
hospitalisations (Murphy et al. 2011).  
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Evidence about adverse effects of therapy for 
asthma during pregnancy 
Although the safety of medications used to treat asthma in pregnant women cannot be 
unequivocally proven (GINA 2011), there is unambiguous evidence for adverse perinatal 
outcomes in women with poorly controlled asthma who do not take regular preventer 
treatment. A recent meta-analysis found that use of medicines such as ICS, long-acting beta-
agonists (LABAs) and cromones during pregnancy was not associated with any particular 
adverse events, although the fluticasone/salmeterol combination had been associated with 
poor outcomes in some post-marketing studies (Lim et al. 2011b). The authors concluded 
that, although some negative outcomes of these medications have been reported, their direct 
link with medication use is inconclusive due to the confounding effect of asthma severity. 
They recommended that selection of therapy should be based on a balance of the risks and 
benefits of medication use versus the risks of poor asthma control (Lim et al. 2011b). 
One study found that high doses of ICS (>1000μg/day) during the first trimester may be 
linked to a risk of congenital malformations. However, when the dose in the first trimester 
was below 1000μg/day, there was no greater risk of congenital malformations than for the 
general population (Blais et al. 2009). There are few data on the risk of adverse outcomes 
attributable to use of LABA, combination ICS/LABA therapy, leukotriene receptor 
antagonists or cromones during pregnancy (GINA 2011; Lim et al. 2011b). 
Despite limited evidence of adverse effects of treatment for asthma during pregnancy, many 
women and their doctors remain concerned. A qualitative study of pregnant mothers with 
asthma at John Hunter Hospital, Newcastle, revealed that perception of risk of asthma 
medication to their unborn baby was overestimated compared with the actual risk (Powell et 
al. 2011). There is also evidence of under-prescribing of asthma medications during 
pregnancy (Lim et al. 2011a). 
Management of asthma during pregnancy 
Clinical practice guidelines 
There are several current national and international guidelines and recommendations that 
are relevant to the management of asthma during pregnancy; these are summarised in Boxes 
2.2 and 2.3.  
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Box 2.2: Summary of current Australian guidelines and recommendations for 
asthma management relevant to management during pregnancy 
Standards for Maternity Care in Australia and New Zealand (Royal Australian and  
New Zealand College of Obstetricians and Gynaecologists 2011) 
x Women with complex medical conditions which include asthma must be managed by 
a consultant obstetrician.  
x A system of clear referral guidelines and pathways should be established so that 
pregnant women who require additional care are cared for and treated by the 
appropriate specialist. 
x Multidisciplinary care, provided through well-understood clinical and local social 
service networks, should be available for all women with pre-existing medical 
conditions. 
Asthma Management Handbook (National Asthma Council Australia 2006) 
x Close cooperation between all health professionals caring for the pregnant patient is 
important to ensure the best asthma management. 
x Peak expiratory flow monitoring and regular review of asthma every 4–6 weeks is 
recommended. This can provide reassurance for the pregnant woman and her 
healthcare providers.  
x The pharmacological treatment of asthma during pregnancy should be the same as for 
non-pregnant women. 
x Doses of ICS should be the minimum necessary to control symptoms and maintain 
normal or best lung function. Trigger factors should be avoided or minimised where 
possible. Minimise exposure to known allergens and irritants. 
x Acute asthma exacerbations may reduce the amount of oxygen available to the fetus. 
Any deterioration in symptoms should be managed promptly. 
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Box 2.3: Summary of current international guidelines and recommendations for 
asthma management relevant to management during pregnancy 
British Guideline on the Management of Asthma: A National Clinical Guideline  
(British Thoracic Society 2012) 
x Counsel women with asthma regarding the importance and safety of continuing 
asthma medications in pregnancy to ensure good asthma control. 
x Use ICS, LABA and short acting beta agonists (SABA) as normal during pregnancy. 
x Give drug therapy for acute asthma as for the non-pregnant patient.  
x During acute asthma, give high flow oxygen to maintain saturation between 94–98% to 
prevent maternal and fetal hypoxia.  
American College of Obstetricians and Gynaecologists Practice Bulletin: Clinical 
Management Guidelines for Obstetrician-Gynecologists no. 90 (Dombrowski et al. 2008) 
x The ultimate goal of asthma therapy in pregnancy is maintaining adequate 
oxygenation of the fetus by preventing hypoxic episodes in the mother.  
x Optimal management of asthma during pregnancy includes objective monitoring of 
lung function, avoiding or controlling asthma triggers, educating patients, and 
individualizing pharmacologic therapy to maintain normal pulmonary function.  
x It is safer for pregnant women with asthma to be treated with asthma medications than 
it is for them to have asthma symptoms and exacerbations. 
x ICS are first-line controller therapy for persistent asthma in pregnancy. 
x The step-care therapeutic approach uses the lowest amount of drug intervention 
necessary to control a patient’s severity of asthma.  
Global Strategy for Asthma Management and Prevention (GINA 2012) 
x Focus treatment on control of symptoms and maintenance of normal lung function. 
x Pregnant patients with asthma need to be advised that the greater risk to their baby lies 
with poorly controlled asthma and the safety of most modern treatments should be 
stressed. Provide printed material in relation to this for additional reassurance. 
x ICS have been shown to prevent exacerbations of asthma during pregnancy. 
x Acute exacerbations of asthma should be treated aggressively to avoid fetal hypoxia. 
Working group report on managing asthma during pregnancy: recommendations for 
pharmacologic treatment (NAEPPA and Pregnancy Working Group 2004) 
x Assess and monitor asthma on a monthly basis, evaluating asthma history, lung 
auscultation and objective measures of lung function. Spirometry is recommended at 
initial assessment, with spirometry or peak flow at subsequent visits.  
x Control factors contributing to asthma severity by identifying and avoiding exposure 
to allergens and irritants that lead to asthma exacerbations. 
x Patient education; asthma control is enhanced by ensuring access to education about 
asthma and skills necessary to manage it. This includes self-monitoring, correct use of 
inhalers and following a plan for managing asthma long term and for promptly 
handling signs for of worsening asthma. 
x Stepwise approach to pharmacologic therapy; the dose and number of medications 
and frequency of administration are increased as necessary and decreased where 
possible. 
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Key elements of these guidelines are: 
• review of asthma status every 4–6 weeks during the pregnancy; this includes assessment 
of symptoms, measurements of lung function (peak flow or spirometry) and medications 
review if necessary. This differs from the recommended frequency of asthma review 
every 3–12 months for non-pregnant patients with asthma (NAC 2006).  
• education for the pregnant patient on the use and safety of asthma medications during 
pregnancy and the importance of maintaining good asthma control in order to reduce 
the chance of exacerbations 
• ensuring the pregnant patient knows to avoid relevant asthma triggers and allergens 
where possible to prevent exacerbations 
• appropriate management of worsening asthma in pregnancy, through provision of a 
written asthma action plan, and use of appropriate medications and monitoring for 
exacerbations managed in primary or secondary care.  
Among pregnant women with asthma, regular use of ICS reduces the risk of severe 
exacerbations of asthma (Dombrowski et al. 1996; Murphy et al. 2006). Cessation of regular 
use of ICS during pregnancy increases the risk of deterioration in asthma control and the 
occurrence of severe exacerbations of asthma (Murphy et al. 2005a).  
ICS are recommended as first-line therapy for asthma in pregnancy (Dombrowski et al. 2008; 
GINA 2011; NAC 2006). The report of the National Asthma Education and Prevention 
Program (NAEPP) in the United States finds that ‘it is safer for pregnant women with asthma 
to be treated with asthma medications than it is for them to have asthma symptoms and 
exacerbations’ (NAEPP 2007). 
Exacerbations of asthma that occur during pregnancy should be managed in the same way as 
these exacerbations are managed in non-pregnant women (NAC 2006). However, in the 
United States, it has been shown that pregnant women are less likely to receive appropriate 
treatment during an asthma exacerbation than non-pregnant women (McCallister et al. 
2011). 
Existing guidelines recommend that pregnant women have an annual influenza vaccination, 
as they are more susceptible to seasonal influenza (DoHA 2013). As smoking has adverse 
effects on pregnancy outcomes, and also on the control of the asthma, advice on smoking 
cessation is an important part of management of pregnant women with asthma. 
The first module of new National Evidence-Based Antenatal Care Guidelines was released in 
2012 to support Australian maternity services to provide high-quality, evidence-based 
antenatal care to healthy pregnant women. These guidelines refer only briefly to asthma care 
during pregnancy, noting the importance of providing additional care for severe asthma in 
the antenatal period (AHMAC 2012).  
Currently, in Australia, there is no nationally consistent collection of asthma-management 
data in pregnant women, which makes it difficult to assess if there is a gap between 
recommended clinical management of asthma in pregnancy and clinical practice, and, if so, 
to identify and assess the implications of any such gap. 
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3 Developing a monitoring approach for 
asthma in pregnancy 
Existing indicators that are relevant to asthma in 
pregnancy 
The Australian Centre for Asthma Monitoring (ACAM) was established in 2002, with one of 
its objectives being to provide advice on the development of national indicators to monitor 
asthma. The initial work on indicators led to 24 recommended indicators for population 
monitoring (ACAM 2004, 2007; AIHW 2000). Further rigorous work in indicator 
development through a consultative process with asthma experts and stakeholders refined 
the list to 10 core items (ACAM 2009)(Table 3.1). These were considered the most important 
indicators for monitoring asthma at a national level. In addition to these, smoking status is 
important for pregnant women with asthma, and its adverse effects on mother and fetus 
have been well described in the literature (Boulet et al. 2012; Nathan et al. 2012). The list does 
not preclude the use of other indicators where they are relevant to a specific purpose. 
Table 3.1: Core asthma indicators for general population  
Indicator Description 
1 Prevalence of current asthma  Reporting doctor-diagnosed asthma as well as symptoms of or treatment for 
asthma in the last 12 months 
2 Death (all ages) Death due to asthma 
3 Death (5 to 34 years) Death due to asthma among people aged 5 to 34 
4 Hospitalisations Episodes of hospitalisation for asthma 
5 Asthma control A composite indicator developed from measures of symptoms and 
medication use to impute the proportion of people with asthma who have 
poor clinical control 
6 General practice encounters General practice encounters for asthma 
7 Asthma action plans People with asthma who have a written asthma action plan 
8 Quality of life People with asthma who report poor health-related quality of life 
9 Preventer use People with asthma who use preventers (ICS and other similar medicines) 
10 Cost due to asthma An index derived from expenditure and burden of disease data to examine 
the costs of asthma to individuals 
11 Smoking(a)  Current smoking status 
(a) No consensus was reached on smoking status during development of core indicators, but the importance of identifying smoking status in 
pregnant women has been well described in the literature. 
Source: ACAM 2009 
Proposed additional indicators specific to 
pregnancy 
Building on the ACAM’s earlier work, this report proposes three additional indicators 
specific to asthma management in pregnancy for consideration (briefly summarised in Table 
3.2). These indicators can be used in planning and implementation of interventions to reduce 
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the burden of asthma on this subpopulation as well as community at large. These three 
indicators are described in more detail below.  
Table 3.2: Proposed additional asthma indicators for pregnant women  
Indicators Description 
1 Proportion of pregnant women who have the presence 
or absence of current asthma documented 
Documented doctor-diagnosed asthma as 
well as symptoms of or treatment for 
asthma during antenatal care  
2 Proportion of pregnant women with asthma who have 
a review of their asthma during the first trimester 
Provision of asthma review among the 
pregnant women with asthma in the first 
trimester 
3 Proportion of pregnant women with asthma who have 
a 4- to 6-weekly review of their asthma in pregnancy 
Provision of asthma review among the 
pregnant women with asthma throughout 
pregnancy 
Source: ACAM analysis of literature.  
Proportion of pregnant women who have the presence or absence 
of current asthma documented 
Description 
Proportion of women who have their clinical record indicating the presence or absence of 
asthma. 
Numerator: Number of pregnancy clinical records where the presence or absences of asthma 
are recorded. 
Denominator: Number of pregnancy clinical records. 
Rationale 
As reported in the preceding chapter, there is evidence that, among pregnant women: 
asthma is common; it may have adverse effects on the course of pregnancy and on fetal and 
infant outcomes; it may be adversely affected by pregnancy; and appropriate management is 
important to ensure optimal pregnancy and asthma outcomes.  
The first step to initiating appropriate management for asthma in pregnancy is to record the 
diagnosis of asthma during antenatal care. This indicator is designed to measure the extent 
to which the diagnosis of asthma is sought and recorded during antenatal care.  
Proportion of pregnant women with asthma who have a review of 
their asthma during the first trimester 
Description 
The proportion of pregnant women with asthma who have documented evidence of a 
review of their asthma status (level of control) and management (prescription of appropriate 
preventer medications, avoidance of trigger factors, possession of a written asthma-
management plan, and education about use and safety of medications) during the first 
trimester of pregnancy. 
Numerator: Number of pregnant women who have a documented review of their asthma 
within their first trimester of pregnancy. 
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Denominator: Number of pregnancy clinical records. 
Rationale 
As outlined in the previous chapter, there is evidence that asthma control may change 
during pregnancy and that effective asthma management improves both asthma outcomes 
and pregnancy outcomes. The aspects of assessment and management measured by this 
indicator are important elements of caring for patients with asthma during pregnancy and 
are recommended in clinical practice guidelines.  
Proportion of pregnant women with asthma who have a 4- to  
6-weekly review of their asthma in pregnancy 
Description 
The proportion of pregnant women with asthma who have documented evidence of a 
review of their asthma control at 4- to 6-weekly intervals between the initial assessment and 
delivery.  
Numerator: Number of pregnant women with asthma who have documented reviews on 
their pregnancy clinical record 
Denominator: Number of pregnancy clinical records. 
Rationale 
As outlined in the previous chapter, there is evidence that asthma control may change 
during pregnancy and that effective asthma management improves both asthma outcomes 
and pregnancy outcomes. Exacerbations or worsening control may occur at any time during 
pregnancy, particularly during the second trimester. Clinical practice guidelines recommend 
that asthma is reviewed at 4- to 6-weekly intervals during pregnancy, whereas for the 
general asthma population, review at 3- to 12-monthly intervals is recommended. 
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4 Data sources that could be used within 
a monitoring approach 
Existing data sources 
AIHW National Perinatal Data Collection and National Maternity 
Data development project 
The National Perinatal Data Collection (NPDC) is a national population-based collection of 
data on pregnancy and childbirth. The NPDC is derived from data reported to the perinatal 
data collections in each state and territory in Australia. Midwives and other staff complete 
notification forms for each birth, usually at the time of delivery, using information obtained 
from mothers and from hospital or other records. Selected data from these state and territory 
collections are compiled annually into the national data set by the AIHW’s National 
Perinatal Epidemiology and Statistics Unit (Perinatal and Reproductive Epidemiology 
Research Unit 2012).  
The Perinatal National Minimum Data Set (NMDS) specifies perinatal data elements for 
mandatory collection and reporting at a national level, and depends on national agreement 
to collect the data in a standardised way (Perinatal and Reproductive Epidemiology 
Research Unit 2012). The Perinatal NMDS was first specified in 1997. It includes data items 
relating to the mother, including demographic characteristics, factors relating to the 
pregnancy, labour and birth, and data items relating to the baby, including birth status, sex 
and birthweight (Perinatal and Reproductive Epidemiology Research Unit 2012).  
The National Maternity Data Development Project being carried out by AIHW in 
collaboration with National Perinatal Epidemiological Statistics Unit aims to develop a 
nationally consistent maternity data collection in Australia. One aspect of this project was to 
update the Maternity Information Matrix (MIM): an electronic inventory of maternity data 
collections in Australia. The MIM was formed from a review of existing national and 
jurisdictional data collections and reporting practices nationwide in 2010. The MIM provides 
a list of data collections, data items, and a comparison of metadata and data collection 
overviews. 
The MIM was reviewed to determine whether asthma status was recorded in any of the 
maternity data collections in Australia, as information on the presence of asthma in 
pregnancy is not included in the Perinatal NMDS. 
The presence of asthma during pregnancy is recorded in the maternity data collections of 
three states (Queensland, Western Australia and South Australia) (Maternal Information 
Matrix 2012). If this practice were to be extended to the other states and territories, it would 
be possible to monitor the first of the proposed indicators: the proportion of pregnant 
women who have their asthma status documented.  
Western Australia is able to link the data from the Midwives Notification of Case Attended 
(which asks specifically about asthma) with other data sources such as the state hospital 
morbidity data collection and the emergency department data collection. This could provide 
valuable information on the prevalence of current asthma among pregnant women and, 
potentially, the rate of attendance at emergency departments and rate of hospitalisations 
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among pregnant women with asthma. However, the validity of these data as an indicator of 
the prevalence of asthma in pregnancy has not been assessed. The validity would be limited 
by the accuracy of information that is available to the midwife at the time of delivery.  
Table 4.1: Proportion of pregnant women who had their asthma status recorded in Qld, WA and SA  
State Disease recorded Asthma recorded 
  Count per cent 
Queensland, 2009 Asthma 1,294 2.1 
Western Australia, 2009 Respiratory system diseases 3,463 11.3 
South Australia, 2010 Asthma 1,217 6.2 
Note: The Western Australia midwives notification system asks specifically about asthma, but the annual report only contains respiratory disease. 
 
Source: Personal communication between ACAM and state/territory health authorities.  
National Hospital Morbidity Database  
The National Hospital Morbidity Database (NHMD) is an administrative data set maintained 
by the AIHW. It is a collection of information about care provided to patients admitted to 
Australian hospitals. The NHMD contains information on diagnosis, demographic 
characteristics, procedures performed and duration of stay for episodes of care for patients 
admitted to hospital. In addition, states and territories hold identifiable, unit record data on 
hospitalisations that can be used for data linkage purposes.  
The validity of these data as an indicator of the proportion of pregnant women who have 
had their asthma status documented is limited by the fact that hospital admissions are 
counted per separation and they do not equate to individuals. The diagnostic information is 
only relevant to the current presentation to hospital. Any conditions that were not actively 
managed during the episode of hospital care are not recorded.  
Over the period from 1 July 2008 to 30 June 2011, asthma (defined using the ICD-10-AM 
codes J45 and J46) was recorded as a principal or additional diagnosis in 0.21% of all 
pregnancy-related admissions (defined using the ICD-10-AM codes O10 to O99 and Z33 to 
Z39) in women aged 15–49. This confirms the under-enumeration of asthma among pregnant 
women in the NHMD. 
A further constraint on the use of this data set is that, at a national level, maternal 
characteristics, such as asthma status, cannot be linked to child characteristics and therefore 
analysis of the impact of maternal asthma on the infant cannot be analysed. Systematic 
linkage of maternal and infant records using the NHMD alone is not possible, as it would 
require linking episodes of care for the same woman during pregnancy, childbirth and 
postnatally. This can only be achieved by linking sets of maternal pregnancy records and 
infant records with the perinatal data collection that has records identifying both the mother 
and the baby. In this way, the NHMD could contribute to monitoring asthma and pregnancy 
outcomes. This has been suggested for evaluation of other maternal comorbidities but it is 
not a current feature of this database (AIHW 2010.) 
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Emerging possibilities for data collection 
Hand-held pregnancy record 
The hand-held pregnancy record is a personal copy of notes taken during antenatal and 
medical visits that is maintained by the woman. This system of recording visits is currently 
being used in Western Australia and is the main system in South Australia. At each visit, 
routine checks are recorded in the hand-held pregnancy record. The record is created and 
issued by either the woman’s general practitioner (GP) or other health-care provider at the 
first antenatal visit after confirmation of her pregnancy (NHMRC 2010). 
There is evidence to suggest that this method of record keeping enables greater access to 
information, supports continuity of care, facilitates communication and promotes greater 
responsibility and control by the woman.  
These records are then transferred into the clinical notes of the woman at the hospital where 
she gives birth. The South Australian Department of Health is investigating an opportunity 
to create a web-based format complementing the hard copy version to provide a real-time 
patient record (NHMRC 2010). 
This hand-held record could provide an opportunity to record information such as the 
asthma indicators as detailed in Chapter 3 Proposed additional indicators specific to pregnancy 
and could contribute to greater information on management of other comorbidities in 
pregnant women (NHMRC 2010)  
General practice data 
Despite its critical importance, national data development in Australian primary health-care 
system has not been as well advanced as other parts of the health system. As a result, only 
limited national statistics are available to describe how asthma is managed in the primary 
health-care system.   
The existing Bettering the Evaluation and Care of Health (BEACH) Survey is currently the 
only national data source describing what occurs during patient visits with GPs. The BEACH 
Survey was assessed for its potential to support measurement of the proposed asthma 
management in pregnancy indicators. However, the survey methodology (including how 
problems managed during GP-patient encounters are recorded and resulting 
underestimation of pregnant women with asthma) means it is not suitable for this purpose. 
For further information on the BEACH Survey, see AIHW: Britt et al. (2010) and AIHW 
(forthcoming).  
The vast majority of general practices in Australia use clinical information software to record 
selected details of GP-patient encounters (AIHW 2008). This information is not currently 
collated in a systematic way at the national level. However, the Australian Primary Care 
Collaboratives Program (run by the Improvement Foundation) has been improving data 
collection according to an established methodology for some time. Although this process 
does not produce fully standardised data, it illustrates that collation of primary health-care 
information is feasible. Various Medicare Locals are also collating such data, together with 
other relevant data sources, to understand and improve the quality of services in their 
jurisdiction. Further standardisation and sharing of such information, in keeping with 
patient privacy and confidentiality, and with appropriate standardisation of data items, 
could support much greater understanding of management of asthma and other chronic 
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diseases during pregnancy in future (del Fante et al. 2006; Kelly et al. 2009; Pearce et al. 
2011). 
In July 2012 the Australian Government launched the National eHealth Record System and 
associated Personally Controlled Electronic Health Record (PCEHR) system. One of the key 
clinical documents shared via the PCEHR System is an individual’s Shared Health Summary 
(SHS), which aims to make health-care information available to consumers and all of their 
health-care providers across place and time (AIHW 2008). It is possible that future 
developments in this area, particularly associated with the SHS, will enhance availability of 
information about asthma management in pregnancy. The SHS is created by the patient’s 
regular medical practitioner (for example, GP, registered nurse or Aboriginal health worker) 
and is designed to be a curated record of the patient’s current medical conditions, 
medications, allergies and immunisations at a point in time. There are a number of issues 
that would need to be resolved (such as increases in uptake of the SHS and standardised 
collation of information) before such information would be useful for monitoring purposes.  
Specific local studies 
There are few local studies that describe the management of asthma in pregnancy. A 
population-based survey conducted at the Royal Women’s Hospital, Melbourne, collected 
information about changes in use of asthma medicines during pregnancy. Pregnant women 
with self-reported asthma were invited to complete an anonymous questionnaire during 
their 36th week antenatal visit. Women aged 18 or under and those were unable to 
communicate in English were excluded (Sawicki et al. 2012) (see Table 4.2).  
A study conducted at John Hunter Hospital, Newcastle, collected information on asthma 
self-management skills (Murphy et al. 2005a) among pregnant women with doctor-
diagnosed asthma who were assessed between 20 and 33 weeks gestation.  
The Childhood Asthma Prevention Study, conducted in western and south-western Sydney, 
has reported data on ICS among pregnant women with asthma (Mihrshahi et al. 2007). 
Mothers were assessed in late pregnancy.  
Table 4.2: Australian studies that have data relevant to proposed indicators 
Study Region or hospital Asthma recorded 
(per cent)  
Action plan  Proportion using ICS  
Sawicki et al. 2012  
(n = 819) 
Royal Women’s 
Hospital, Melbourne 
104 (12.7%) n.a. 19/102 (18.6%) 
Murphy et al. 2005  
(n = 211) 
John Hunter 
Hospital, Newcastle 
All subjects had 
asthma 
32 (15.2%) 135 (64.0%) 
Mihrshahi et al. 2003 
(South West Sydney, n = 
616) 
South West Sydney 340/611 (55.6%)(a) n.a.  95/314 (30.3%) 
(a) Pregnant women recruited for study by Mihrshahi et al. were those whose unborn children were at high risk of developing asthma (that is, 
pregnant women with asthma or pregnant women whose partners or other children had current symptoms of asthma), hence the high proportion of 
asthma recorded in this population.  
Sources: Mihrshahi et al. (2003); Murphy et al. (2005a); Sawicki et al. (2012). 
   Monitoring asthma in pregnancy: a discussion paper 17 
These data are limited by their small sample size, local population base and single instance 
of study. However, it is likely that they do provide useful information about the 
management of asthma during pregnancy in Australia.   
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5 Discussion 
Options for data development 
In the preceding chapters, this report has described what good care for asthma during 
pregnancy looks like and how this is related to important outcomes for both the mother and 
infant. The report has also described the information that would be required in a monitoring 
approach designed to ascertain who is getting good care for asthma during pregnancy and to 
identify opportunities for improving care for pregnant women with asthma. Finally, the 
report has described the currently available data sources that might inform a monitoring 
approach for asthma in pregnancy.  
At present, most of the identified indicators in the proposed monitoring approach cannot be 
measured using the available data sources.  
One option for measuring existing core asthma indicators on deaths, hospitalisations and 
preventer medication use among pregnant women would be to investigate the feasibility of 
linking existing perinatal data collections to the National Death Index (AIHW 2013), hospital 
morbidity data (AIHW 2012) and Pharmaceutical Benefits Scheme data (ACAM 2011), 
respectively. At present, this type of linkage is undertaken in some jurisdictions, but not 
nationally. Options for measuring the other key indicators—namely asthma control, GP 
visits, possession of written asthma action plans, recording of asthma status and the 
frequency and timing of asthma reviews—include: 
• augmenting data collection by midwives for the NPDC 
• enhancing general practice data 
• conducting periodic surveys in the antenatal setting. 
Augmenting existing national perinatal data 
It may be feasible to ask midwives to provide the following information to the NPDC:  
• for all pregnant women: 
– whether or not the woman has ever had asthma 
• for women with asthma: 
– their asthma status (current asthma, past asthma)  
– the date on which asthma was first documented during antenatal care 
– the date of first asthma review. 
The NPDC could then report: 
• for all pregnant women: 
– whether asthma status has been documented 
– asthma status (current asthma, past asthma, no asthma), if asthma status has been 
documented. 
• for women with current asthma: 
– gestational age when asthma was first documented 
– gestational age when asthma was first reviewed. 
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The validity of these data would be limited by the variable availability of complete antenatal 
records at the time of delivery, when the perinatal data collection is usually completed. It 
seems unlikely that other information about asthma could feasibly be recorded by midwives.  
Enhancing general practice data  
One possible option for improving general practice data is to conduct targeted surveys of 
GPs to record information about asthma status, control and management (that is, use of 
preventer medications and possession of written asthma management plans) in all pregnant 
women with asthma. A survey such as this could also collect information on the timing and 
frequency of asthma status reviews during pregnancy.  
Other options to enhance Australian general practice data are to consider systematically 
collating information from GP software systems, particularly focusing on information that is 
targeted for inclusion on the Shared Health Summary to reduce burden on information 
suppliers and leverage off existing investments in GP information.  
Conducting periodic surveys in the antenatal setting  
Surveys of pregnant women with asthma, such as those previously reported from antenatal 
care settings in Melbourne, Newcastle and Sydney, may be the most efficient way to collect 
information on the management and control of asthma during pregnancy.  
Conclusion regarding data collection 
Based on currently available information, it seems that the most feasible, and probably the 
most cost-effective, method of collecting data to monitor asthma and the management of 
asthma during pregnancy would be to enhance data collection by midwives. Other 
potentially feasible methods would be periodic surveys in general practice or antenatal 
settings. However, formal assessment of the relative feasibility and cost of these data 
collection vehicles was not within the scope of this project. 
The NPDC is currently undergoing enhancements to support information needs required 
under the Maternity Services Plan 2010–2015. A number of items related to morbidity during 
pregnancy will be captured through these enhancements. On the basis of this report, the 
relevant information committee will be approached to determine the feasibility of adding 
asthma as an additional comorbidity as part of these data collection enhancements.  
Relevance to other common, chronic and complex 
conditions managed during pregnancy 
Diabetes and hypertension are long-term and complex conditions that are common in 
pregnant women. Like asthma, they have an important interaction with pregnancy in that 
they may be triggered or exacerbated by pregnancy and they may have an adverse effect on 
pregnancy outcomes, both for the mother and the infant. Also, like asthma, their 
management may be complicated by pregnancy. Other conditions such as heart disease, 
epilepsy and renal failure have a similar relationship to pregnancy, but are less common 
than asthma, diabetes and hypertension among pregnant women.  
The monitoring approach that has been proposed here for asthma in pregnant women, as 
well as the options for implementing this approach, may be of assistance in developing 
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approaches for monitoring other chronic conditions in pregnant women. Examining these 
conditions in detail with a view to extending the proposed data development options to 
include these conditions may produce cost efficiencies. If a suite of conditions could be 
measured by the same instrument, the data collected would also enable ascertainment of 
who is getting good care for all these conditions during pregnancy, and identification of 
opportunities for improving care for pregnant women with these conditions. 
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Glossary 
asthma: A chronic inflammatory disorder of the airways. Chronically inflamed airways are 
hyperresponsive; they become obstructed and airflow is limited (by bronchoconstriction, 
mucus plugs and increased inflammation) when airways are exposed to various risk factors 
(GINA 2010). 
asthma severity: Severity is defined by the intensity of treatment required to achieve good 
asthma control. Mild asthma is asthma that can be well-controlled with reliever medications 
alone or with low-dose inhaled corticosteroids. Severe asthma is asthma that requires high- 
intensity treatment with inhaled corticosteroids and long-acting beta2-agonists to maintain 
good control, or that is not well controlled despite such treatment (Reddel et al. 2009) Several 
different definitions of asthma severity have been used in the past (Taylor et al. 2008). 
auscultation: The action of listening to sounds of the heart, lungs or other organs, typically 
with a stethoscope. 
BEACH (Bettering the Evaluation and Care of Health) survey: A continuous cross-sectional 
paper-based data collection that collects information for individual patient visits about the 
reasons for seeking medical care, the type of patients seen, the types of problems managed 
and treatment provided in general practice across Australia. 
birthweight: The first weight of the baby (stillborn or live born) obtained after birth. 
Birthweight is usually measured to the nearest 5 g and obtained within 1 hour of birth. 
confidence interval (CI): A statistical term describing a range (interval) of values within 
which we can be ‘confident’ that the true value lies, usually because it has a 95% or higher 
chance of doing so.  
current asthma: Reporting ever being diagnosed asthma by a doctor or nurse, and reporting 
having any symptoms of asthma or taking treatment for asthma in the previous 12 months. 
Other definitions have been used in some surveys, but this is the definition recommended by 
the Australian Centre for Asthma Monitoring (ACAM 2009). 
cromones: Medication (which includes nedocromil sodium and sodium cromoglycate) 
administered by inhalation and used as a prophylactic treatment of asthma. Cromones must 
be taken regularly to produce optimal effect, but they will not relieve acute symptoms. 
Although the mechanism of action of these drugs is not fully understood, they are thought to 
block allergen-induced bronchoconstriction and may be useful in asthma associated with 
allergic factors. They may also be used to prevent exercise-induced bronchoconstriction. 
diabetes: A chronic condition in which the body cannot properly use its main energy source, 
the sugar glucose. This is either due to the pancreas not producing enough of the hormone 
insulin, or the body being unable to effectively use the insulin produced. Insulin helps 
glucose enter the body’s cells from the bloodstream and then be processed by them. Diabetes 
is marked by an abnormal build-up of glucose in the blood and it can have serious short-
term and long-term effects on many of the body’s systems, especially the blood vessels and 
nerves. 
fetus: An unborn child from its 8th week of development. 
gestational age: The time measured from the first day of the woman’s last menstrual cycle to 
the current date. It is measured in completed weeks. A term pregnancy can range from 37 to 
42 weeks 
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gestational hypertension: characterised by the onset of hypertension after 20 weeks 
gestation without any maternal or fetal features of pre-eclampsia followed by return of 
normal blood pressure 3 months after birth. 
infant: A child aged under 12 months.  
inhaled corticosteroids (ICS): Medications widely used in the treatment of airways disease 
to reduce bronchial inflammation and hyperresponsiveness. They reduce symptoms, 
improve lung function and reduce the risk of exacerbations. Inhaled corticosteroids are most 
effective when used on a regular basis, either daily or twice daily. In Australian asthma 
guidelines, inhaled corticosteroids are termed ‘preventers’; in many other countries, they are 
called ‘controllers’. See also preventer medication. 
leukotriene receptor antagonists: Orally administered medications resulting in relaxation of 
smooth muscle and some reduction of the inflammation mediated by leukotrienes. This type 
of treatment may have a place in prevention or treatment of exacerbations of asthma in 
children, but should not be used for acute relief of symptoms. It may also have a role in the 
management of aspirin-sensitive asthma and exercise-induced bronchoconstriction. 
long-acting beta-agonist (LABA): Medication that relaxes the muscles that surround the 
airways and allows for easier breathing. In asthma management, long-acting beta2-agonists 
are recommended for use only in combination with inhaled corticosteroids therapy. The 
action of long-acting beta2-agonists lasts at least 12 hours. 
morbidity: Refers to ill health in an individual and to levels of ill health in a population or 
group. 
mortality: Death. 
outcome (health outcome): A health-related change due to a preventive or clinical 
intervention or service. The intervention may be single or multiple and the outcome may 
relate to a person, group or population or be partly or wholly due to the intervention. 
perinatal: Pertaining to, or occurring in, the period shortly before or up to up to 
28 completed days after birth. 
pre-eclampsia: A complication of pregnancy characterised by high blood pressure and 
protein in the urine. 
pregnancy: The period during which a woman carries a developing fetus in the uterus. 
prescription drugs: Drugs available only on the prescription of a registered medical 
practitioner and available only from pharmacies. 
pre-term delivery: Birth before 37 weeks of gestation 
prevalence: The number or proportion (of cases, instances, and so forth) present in a 
population at a given time. 
preventer medication: A type of medication used to treat asthma to control the disease in 
order to minimise symptoms and exacerbations. 
progesterone: A steroid hormone secreted by the corpus luteum of the ovary, the placenta, 
and also (in small amounts) by the adrenal cortex and testes. It is responsible for preparing 
the inner lining (endometrium) of the uterus for pregnancy. If fertilisation occurs, 
progesterone maintains the uterus throughout pregnancy and prevents the further release of 
eggs from the ovary. 
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reliever medication: A type of medication used in the treatment of asthma to relieve 
symptoms when they occur. 
small for gestational age: Describes a fetus or baby that has failed to reach the birthweight 
expected for its gestational age. This is usually defined as less than the 10th percentile as 
measured on customised charts according to maternal and paternal characteristics. 
spirometry: Measurement of lung function performed by a spirometer. Spirometry is used to 
establish the presence of airflow limitation and its reversibility in response to bronchodilator, 
which is an important feature for the diagnosis of asthma. 
statistical significance: An indication from a statistical test that an observed difference or 
association may be significant, or ‘real’, because it is unlikely to be due just to chance. A 
statistical result is often said to be ‘significant’ if it would occur by chance only once in 
20 times or less often.  
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Asthma in pregnant women may have adverse effects 
on maternal, fetal and infant outcomes, particularly 
if expectant mothers experience an exacerbation of 
asthma while pregnant. Pregnancy, in turn, may have 
adverse effects on asthma control among expectant 
mothers. This report outlines a proposed approach to 
monitoring asthma during pregnancy by capitalising 
on existing data sources as well as identifying data 
development opportunities.
